Dr. Green is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-288-1025
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2004 - 2006
Ohio State University HospitalResidency, Internal Medicine, 2000 - 2003- Ohio State University College of MedicineClass of 2000
Certifications & Licensure
FL State Medical License 2024 - 2026
WA State Medical License 2004 - 2024
MT State Medical License 2021 - 2021
OH State Medical License 2000 - 2005- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2016 Dec 01
- Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma Start of enrollment: 2017 Nov 29
Publications & Presentations
PubMed
- 111 citationsFactors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignanciesJordan Gauthier, Evandro D. Bezerra, Alexandre V. Hirayama, Salvatore Fiorenza, Alyssa Sheih
Blood. 2021-01-21 - 30 citationsAnakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.Nicolas Gazeau, Emily C Liang, Qian Vicky Wu, Jenna M Voutsinas, Pere Barba
Transplantation and Cellular Therapy. 2023-07-01 - 50 citationsConventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consoli...Steven I. Park, Jaideep Shenoi, John M. Pagel, Donald K. Hamlin, D. Scott Wilbur
Blood. 2010-11-18
Journal Articles
- Long Term Follow-up of Tandem Autologous-Allogeneic Hematopoietic Cell Transplantation for Multiple MyelomaParameswaran Hari, Brenda M Sandmaier, Pamela S Becker, Leona Holmberg, Damian J Green, Peter A McSweeney, David G Maloney, Thomas R Chauncey, Haematologica
Abstracts/Posters
- Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Re...Damian J. Green, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple MyelomaDamian J. Green, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)Damian J. Green, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Sajid Javid Working on Radical Plan to Merge Social Care with Health in EnglandOctober 10th, 2021- We Need Even MORE Cash, NHS Bosses Tell BorisSeptember 7th, 2021
- POLITICO London Playbook: AZ vs. EU — What’s 8 Percent in German? — Jabba the CutJanuary 26th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
